Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.47), $0.13 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $17.05 million versus the consensus estimate of $16.09 million.

Guidance:
Enanta is updating its expense guidance at this fiscal year mid-point. Research and development expense is $125 million to $145 million. General and administrative expense is $50 million to $60 million. The research and development expense increase reflects the impact of the company’s new immunology programs as well as additional efforts to accelerate the RSV clinical studies. The general and administrative expense increase is due to additional stock compensation expense and costs associated with pursuing the company’s patent infringement lawsuit.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.